

## EQA round: BIL1/24 - Bilirubin Neonatal

Deadline: 16.2.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D <sub>max</sub> = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N <sub>tot</sub> = total number of the results	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	N <sub>eva</sub> = number of the results assessed
N <sub>out</sub> = number of the results removed before calculation		N <sub>suc</sub> = number of successful results
		S <sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL			
<b>(215) Bilirubin total</b>	[μmol/L]				119							99	96	97
<b>Sample A</b>		207	17	8,3	119							99	96	97
(1) Abbott		209	14	6,7	21	0	CVP	202	3	18%	165	239	21	
(58) Beckman Coulter (AU)		207	9	4,3	22	0	CVP	202	3	18%	165	239	22	
(60) Roche		195	6,5	3,3	49	0	CVP	202	3	18%	165	239	49	
(162) Siemens (Atellica)		242	14	5,9	13	0	CVPG	242	9,6	18%	198	286	0	
(179) Siemens		232	22	9,5	7	0	CVPG	232	21	18%	190	274	0	
Other					7	0							7	
								1x 12, 1x 40, 1x 61, 1x 70, 1x 77, 1x 158, 1x 178						
<b>Sample B</b>		323	25	7,9	119							99	96	97
(1) Abbott		324	17	5,3	21	0	CVP	315	4,5	18%	258	372	21	
(58) Beckman Coulter (AU)		324	11	3,5	22	0	CVP	315	4,5	18%	258	372	22	
(60) Roche		305	12	4,1	49	0	CVP	315	4,5	18%	258	372	49	
(162) Siemens (Atellica)		376	19	5,1	13	0	CVPG	376	13	18%	308	444	0	
(179) Siemens		372	31	8,2	7	0	CVPG	372	30	18%	305	439	0	
Other					7	0							7	
								1x 12, 1x 40, 1x 61, 1x 70, 1x 77, 1x 158, 1x 178						
<b>(216) Bilirubin direct</b>	[μmol/L]				87							77	72	94
<b>Sample A</b>		37,5	7,4	20	87							77	72	94
(1) Abbott		31,3	1	3,3	12	0	CVPG	31,3	0,73	18%	25,6	37	12	
(58) Beckman Coulter (AU)		48,8	2,9	5,9	15	0	CVPG	48,8	1,8	18%	40	57,6	15	
(60) Roche		34,5	3,7	11	39	0	CVPG	34,5	1,4	18%	28,2	40,8	39	
(162) Siemens (Atellica)		39,8	4,1	10	11	0	CVPG	39,8	3	18%	32,6	47	11	
Other					10	0							0	
								4x 0, 1x 70, 1x 158, 4x 179						
<b>Sample B</b>		53,1	9,3	18	87							77	72	94
(1) Abbott		45,5	1,2	2,6	12	0	CVPG	45,5	0,83	18%	37,3	53,7	12	
(58) Beckman Coulter (AU)		67,4	2,9	4,3	15	0	CVPG	67,4	1,9	18%	55,2	79,6	15	
(60) Roche		49,3	5,4	11	39	0	CVPG	49,3	2,1	18%	40,4	58,2	39	
(162) Siemens (Atellica)		57	3,9	6,9	11	0	CVPG	57	2,9	18%	46,7	67,3	11	
Other					10	0							0	
								4x 0, 1x 70, 1x 158, 4x 179						